Theratechnologies Inc (THTX) Return on Assets ROA from the fourth quarter of 2024 to fourth quarter of 2023 and for the year 2024, Average High and Low, Fundamental Ratios from Nov 30 2024 to Nov 30 2023 - CSIMarket
Theratechnologies Inc 's ROA from the fourth quarter of 2024 to the fourth quarter of 2023 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Theratechnologies Inc 's ROA in the fourth quarter of 2024?
Theratechnologies Inc recorded a cumulative net loss of $-8 million during 12 months ending in the fourth quarter of 2024, resulting in a negative return on assets (ROA) of -13.19%.
However, within the Healthcare sector 376 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2024 from to 4060.
In an era where the healthcare landscape is constantly evolving, Theratechnologies Inc. finds itself at a critical juncture, grappling with challenges and opportunities that could shape its future. The Montreal-based biopharmaceutical company, known for its innovative therapies, recently announced a significant supply shortage of its product, EGRIFTA SV (tesamorelin for injection), expected to impact patients at the mid-January 2025 mark. This anticipated shortage stems from a voluntary shutdown of a contract manufacturing facility in late 2024, a move that has led to reported stockouts in several U.S. pharmacies. The urgency surrounding EGRIFTA SV s supply issues highlights a broader concern within the pharmaceutical industry — the risky nature of outsourcing production to contract manufacturers. As patients rely on this crucial therapy, the unexpected halt has raised questions about Theratechnologies’ capacity to manage its supply chain effectively. The company has acknowledged some remaining inventory in certain locations, but the looming shortfall poses the risk of disappointing patients who depend on this treatment.Financially, Theratechnologies has been navigating turbulent waters. As of the fourth quarter of 2023, the company recorded a cumulative net loss of $24 million, showcasing a disconcerting negative return on assets (ROA) of -30.81%. This alarming figure positions Theratechnologies among the bottom ranks of its peers, with 456 other companies within the healthcare sector reporting better financial health. The company s performance has notably deteriorated since the third quarter of 2023, plunging to a dismal ranking of 3897 in ROA.
MONTREAL, Dec. 10, 2024 — Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies, announced today that the United States Food and Drug Administration (FDA) has designated a Prescription Drug User Fee Act (PDUFA) goal date of March 25, 2025, for its supplemental Biologics License Application (sBLA) concerning the F8 formulation of tesamorelin. This pivotal date marks a significant milestone for the company as it seeks to advance its product offering within the competitive landscape of biopharmaceutical therapies.The F8 formulation of tesamorelin is a synthetic HGH-releasing hormone that has shown promise in treating specific medical conditions. The FDA s assignment of a PDUFA date indicates that the agency views the application as ready for review, which could lead to commercial approval if all requirements are met. Should the FDA approve the application, it would unlock new revenue streams for Theratechnologies, providing potential relief from its ongoing financial struggles.
In a recent development, biopharmaceutical company Theratechnologies Inc. has received a refusal to file letter (RTF) from the United States Food and Drug Administration (FDA) regarding the company s supplemental Biologics License Application (sBLA) for an intramuscular (IM) method of administration for the maintenance dose of Trogarzo (ibalizumab-uiyk). This setback comes as the company recorded a significant net loss in the past year, raising concerns about its financial stability. This article aims to outline the facts surrounding these events and assess their impact on Theratechnologies. I. The FDA Refusal to File Letter: On February 27, 2024, Theratechnologies made the announcement that the FDA has issued an RTF letter in response to their sBLA filing for the IM method of administration for Trogarzo. The sBLA filing was initially announced on January 2, 2024. The RTF letter from the FDA indicates that the application did not meet the regulatory requirements for completeness, possibly delaying or hindering the approval process for the new administration method.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
